http://orcid.org/0000-0002-9436-1821
Figures
Abstract
Background
Clostridium difficile infection (CDI) is the most common healthcare associated infection and is highly prevalent in Europe and North America. Limited data is available on the prevalence of CDI in Asia. However, secular increases in prevalence of risk factors for CDI suggest that it may be emerging as a major cause of morbidity, highlighting the urgent need for a systematic study of the prevalence of CDI in Asia.
Methods
We systematically searched PubMed/Medline and Embase for publications from Asia between 2000–16 examining prevalence of CDI. A random-effects meta-analysis was performed to calculate the pooled prevalence of CDI in Asia and to identify subgroups and regions at high risk.
Results
Our meta-analysis included 51 studies from throughout Asia including 37,663 patients at risk among whom confirmed CDI was found in 4,343 patients. The pooled proportion of confirmed CDI among all patients with diarrhea was 14.8% with a higher prevalence in East Asia (19.5%), compared with South Asia (10.5%) or the Middle East (11.1%). There were an estimated 5.3 episodes of CDI per 10,000 patient days, similar to rates reported from Europe and North America. Infections due to hypervirulent strains were rare. CDI-related mortality was 8.9%.
Citation: Borren NZ, Ghadermarzi S, Hutfless S, Ananthakrishnan AN (2017) The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact. PLoS ONE 12(5): e0176797. https://doi.org/10.1371/journal.pone.0176797
Editor: Abhishek Deshpande, Cleveland Clinic, UNITED STATES
Received: January 17, 2017; Accepted: April 17, 2017; Published: May 2, 2017
Copyright: © 2017 Borren et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The minimal dataset is within the Supporting Information file.
Funding: Ananthakrishnan has served on the scientific advisory boards for Cubist pharmaceuticals and Merck and has received research funding from Merck. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Ananthakrishnan has served on the scientific advisory boards for Cubist pharmaceuticals and Merck and has received research funding from Merck. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Introduction
Clostridium difficile infection (CDI) is the most common healthcare associated infection (HAI). Since its identification as the cause of pseudomembranous colitis in 1978[1], it has emerged as an important cause of morbidity particularly among hospitalized patients and led to epidemics with high mortality. An estimated 453,000 infections occur annually in the United States, 172,000 in Europe, and 18,005 in England.[2–4] Recognition of the burden of CDI has led to a multi-pronged strategy of provider education, institution of systematic testing, antibiotic stewardship and infection control programs which has blunted the rise, and even reduced the incidence of this infection in North America and Europe.[5, 6]
In contrast, little is known about the prevalence and impact of CDI in Asia as few systematic studies exist and testing remains infrequent, hampered by both a low index of clinical suspicion and the lack of readily available laboratory testing.[7] Yet, several factors favor the possible emergence of C. difficile as an important pathogen in Asia.[8, 9] While traditionally considered home to a young population, with improved life expectancy and control of other infectious diseases, many countries in Asia are witnessing an aging of their demographics and in most studies, the elderly are particularly susceptible to CDI.[10, 11] Chronic diseases, also a risk factor for CDI, have increased in prevalence, and so has the need for frequent healthcare contact and hospitalizations. In addition, antibiotic use, the strongest risk factor for CDI, is often indiscriminate and unregulated in some Asian countries.[12, 13]
Thus, there is an important need for systematic study of the prevalence and impact of CDI in Asia to inform both clinical practice as well as healthcare policy. We performed this systematic review and meta-analysis to (1) quantify the burden of CDI among countries in Asia; (2) identify subgroups and regions at high risk within this population; and (3) define the proportion of hypervirulent epidemic strains of C. difficile; and (4) quantify CDI-related mortality in comparisons to studies from the west.
Methods
Literature search
We conducted a systematic search of the MEDLINE/PubMed and EMBASE databases for studies providing prevalence or incidence rates of CDI in Asia. To quantify current burden, our search was limited to publications from January 2000 to June 2016. No language restrictions were applied in our search, but inclusion of the study in our full analysis required at least the abstract to be available in English. Our search strategy combined 3 different phrase groups by using the Boolean operator “AND” (S1 Table). The first search group consisted of terms relevant to identify CDI and included combination of “Clostridium difficile”, “C difficile” and “C diff” and “Pseudomembranous colitis”. The second group defining location included both broadly the phrase “Asia” as well as specific countries within Asia including China, Hong Kong, India, Iran, Israel, Japan, Korea, Malaysia, Singapore, Taiwan, Thailand and Turkey. The final search terms defined the outcome of interest and included “prevalence”, “incidence”, “epidemiology”, and “frequency”. The citation list from all eligible studies and reviews were also perused to identify other relevant studies.
Inclusion and exclusion criteria
Studies were eligible for inclusion if they provided information on the incidence of CDI in Asia reported either as proportion of tests positive for toxigenic C. difficile among symptomatic patients testing, per 1000 hospital discharges, or per 10,000 patient days. Studies examining C. difficile carriage among asymptomatic individuals were excluded. Eligible studies could include either an inpatient or outpatient population.
Data collection
The decision for inclusion of each study was made by two authors (NZB and ANA) who independently screened the studies by title and abstract. The following data were extracted from each study: year of publication, location, setting (inpatient or outpatient), population (nosocomial diarrhea, antibiotic-associated diarrhea, other), number of patients tested, and number of patients with confirmed CDI. The microbiological method for diagnosis of CDI was noted and where available, the results of molecular characterization for specific ribotypes. From each study, mean age prevalence of risk factors for CDI including exposure to antibiotics, use of proton pump inhibitors (PPI), and recent hospitalization were noted. Studies were grouped into three geographic regions: South Asia (India, Malaysia, Pakistan, Singapore, and Thailand), East Asia (China, Hong Kong, Japan, Korea, Taiwan) and the Middle East (Iran, Jordan, Kuwait, Lebanon, Qatar, Turkey). When necessary, attempts were made to contact the corresponding authors for additional pertinent information.
Outcomes
The primary outcome of interest was expressed in one of three ways: (1) the proportion of tests positive for toxigenic C. difficile from among all patients with diarrhea; (2) rate of CDI per 1,000 admissions; and (3) the rate of CDI per 10,000 patient days. Our secondary outcome was CDI-associated mortality.
Assessment of study quality
We used the Newcastle-Ottawa Quality Assessment Scale (NOS) to assess study quality. This scale ranks studies in 3 groups based on the selection of the cohort; the comparability of the cohorts; and the completeness of ascertainment of the outcome. Each study could receive up to 4 stars. Studies were considered representative if they consisted of an unselected group of patients and did not focus on individuals with specific comorbidities alone. Ascertainment bias was considered to be absent if all patients with diarrhea underwent similar testing strategies; reliance on clinical suspicion to trigger testing for select patients was deemed susceptible to bias.
Statistical analysis
Heterogeneity between the studies was determined using the Cochran’s Q and I2 statistics. An I2 > 50% or p < 0.10 indicated significant heterogeneity. A DerSimonian and Laird random effects model was used for all analyses to determine the pooled prevalence rates (and 95% confidence intervals (CI)) for proportion of stool tests that were positive for C. difficile as well as rates per 1,000 admissions and 10,000 patient days. Pre-specified subgroup analysis was performed stratifying by setting, geographic region, and population under study (antibiotic-associated diarrhea, all nosocomial diarrhea). Publication bias was examined using the Egger test and visual examination of the funnel plot. Sources of heterogeneity between studies were identified by performing a meta-regression. All data were recorded in a Microsoft Excel spreadsheet (Microsoft Corp, Redmond, WA) and statistical analysis carried out using Stata 13.2 (StataCorp, College Station, TX).
Results
Literature search
Our search of MEDLINE/Pubmed yielded 448 citations. Of these, 393 citations were excluded on initial screening of the title and abstract and the full text of remaining 55 articles were reviewed (Fig 1). Two articles representing duplicate data[14, 15], 2 with insufficient information[16, 17], and 4 examining C. difficile carriage in healthy individuals were excluded[18–21], resulting in a final cohort of 48 unique studies.[9, 22–71] Of these, only the abstract was available for review in English in 7 studies but sufficient relevant information could be extracted to allow for inclusion.[60–66, 71] A search on Embase yielded 3 additional studies that were eligible for inclusion. One large study from Thailand was not included as it did not include microbiological confirmation of CDI.[72]
Study characteristics
The characteristics of the included studies are summarized in Table 1. Forty two included only hospitalized patients[9, 22–24, 28–40, 42, 43, 46, 48, 50–55, 57, 59–67, 69–71], 1 was exclusively among outpatients[47], and 8 included both groups.[25, 26, 41, 44, 45, 49, 56, 68] A total of 16 countries were represented, with China contributing the largest number of studies. Twenty-five studies were from East Asia[9, 22, 24, 26, 28, 34–37, 39–42, 44, 52–54, 56, 58–61, 67, 70, 71], 16 from South Asia[23, 25, 27, 29, 31, 33, 43, 46, 51, 55, 62–64, 66, 68, 69] and 10 from the Middle East.[30, 32, 38, 45, 47–50, 57, 65] The mean age of included patients was 60 years (data from 24 studies) and just fewer than half the cohort were women (43%, 34 studies). From 28 studies presenting data on antibiotic use; a mean of 84% of patients had been exposed recently (range 26–100%). Sixteen studies examining PPI use yielded a mean proportion of 49% (range 5–90%). From twenty-one studies where this data was available, the pooled proportion of recent hospitalization was 71% (range 19–100%).
The included studies varied in the testing modality to determine CDI. The most commonly performed tests were anaerobic or toxigenic culture (71%) and the enzyme immunoassay (EIA) (52%). Nearly half the studies also reported using polymerase chain reaction / nucleic acid amplification test (PCR-NAAT) (51%). Other diagnostic tests used were cell culture cytotoxicity neutralization assay (CCNA) (8%), glutamate dehydrogenase assay (GDH) (6%), and lower gastrointestinal endoscopy (11%). Molecular characterization of C. difficile ribotype was performed in one-third of the included studies (n = 15). The mean proportion of infections due to ribotype 027 was 0.3% (range 0–2.1%) and from 12 studies, the proportion of ribotype 017 was 14% (range 0–48%).
Proportion of C. difficile positivity
This pooled analysis included 37,663 patients tested among whom CDI was confirmed in 4,343 patients. The overall pooled C. difficile positive rate was 14.8% (95% CI 12.9–16.7%) (Fig 2). However, there was significant heterogeneity between the studies (I2 = 96.3%, p<0.001), with rates from individual studies ranging from 2.0% to 61.4%. The pooled proportion of CDI was greater in the 37 studies restricted to hospitalized patients (16.4%, 95% CI 14.1–18.7%) than those with a mixed inpatient-outpatient population (11.1%, 95% CI 7.9–14.4%). The single study examining outpatients alone reported a significantly lower prevalence of 5.3% (p < 0.001)[47]. The prevalence of CDI was greater among studies restricting testing to antibiotic-associated diarrhea (25 studies, 20.9%) compared to all hospitalized patients with diarrhea (33 studies, 13.5%; p < 0.001).
There was significant regional variation in occurrence of CDI. The proportion of C. difficile positivity was significantly higher among studies from East Asia (19.5%, 95% CI 15.5–23.5%, 21 studies) compared to those from the Middle East (11.1%, 95% CI 7.8–14.4%, 9 studies) or South Asia (10.5%, 95% CI 7.9–13.1%, 16 studies) (p < 0.001) (Fig 3, S1 Fig).
Rates of C. difficile infection among hospitalized patients
Eighteen studies provided extractable data on incidence per 1,000 admissions, yielding a pooled rate of 3.2 cases of CDI per 1,000 admissions (95% CI 2.4–3.9). However there was significant heterogeneity between the studies (I2 = 99.3%). Eleven studies provided sufficient information to estimate the incidence rate of CDI per 10,000 patient days. This yielded a pooled incidence of CDI of 5.3 per 10,000 patient-days (95% CI 4.0–6.7) (Fig 4). Excluding one study conducted exclusively in a high risk ICU population did not significantly alter the pooled incidence (4.9 per 10,000 patient days).[36]
Outcomes of CDI
Thirteen studies provided information on CDI-related mortality (range 30–180 days).22,24,28,36,41,44,45,49,57–60,62 The random effects pooled rate of CDI-related death was 8.9% (95% CI 5.4%– 12.3%).
Meta-regression
As most studies reported proportion of C. difficile positive tests as their outcome, meta-regression to identify influential covariates were performed for this outcome. Only geographic region of origin achieved statistical significance while there was a trend towards significance for the proportion of patients recently (S2 Table). Study setting, number of included patients, year of study, and proportion of patients exposed to antibiotics or PPI were not associated with rate of CDI. Specifically, we also did not identify a temporal trend over time in the proportion of stool tests that were positive for C. difficile (S2 Fig).
Study quality and publication bias
S3 Table presents the quality scores for the included studies. While not all fields of the NOS were applicable for our meta-analysis, all studies were deemed of adequate quality to be included in the analysis. Begg and Egger tests both showed significant likelihood of publication bias (p = 0.046 and p<0.001, respectively) (S3 Fig).
Discussion
The contribution of CDI to morbidity and mortality among hospitalized patients is well recognized in North America and Europe. However, little is known about whether C. difficile is equally prevalent and consequential in Asia. A systematic study of this is important to not only accurately quantify the burden of CDI in a population witnessing an increase in many of its risk factors, but also essential to inform disease surveillance and interventions to prevent the dramatic rise in incidence noted elsewhere.
Our systematic review demonstrated a pooled prevalence of CDI of 14.8% among all patients tested and 16.4% among hospitalized patients with diarrhea. These findings are similar to the estimates from other regions. In a multi-country European surveillance study, the proportion of stool samples positive for C. difficile ranged from 4 to 39%[73]. A multicenter study by the Centers for Disease Control (CDC) in the United States performing surveillance for C. difficile revealed a similar rate of positive tests, ranging from 7% to 20%.[74] In a nationwide study from Spain analyzing 807 stool specimens, 7.8% were found to be positive for C. difficile.[75]
The pooled incidence rate of CDI from Asia in our meta-analysis was 5.3 per 10,000 patient days. This is similar to reports from western countries. In a multicenter study from Europe, the incidence of CDI was reported as 4.1 per 10,000 patient days.[73] In the EUCLID study, the mean incidence rate was similarly 7 per 10,000 patient days with estimates from individual countries varying from 0.7 to 28.7.[76] A nationwide systematic study from Spain placed the rate at 3.8 per 10,000 patient-days.[75] The incidence is similar in the United States with a median hospital-onset CDI rate of 5.4 per 10,000 patient days.[77] As well, the pooled CDI-related mortality rate of 8.9% is also comparable to western estimates; for example, Lessa et al. reported a mortality rate of 6.4% in a systematic study from the United States.[78] Thus, despite the perception of CDI being uncommon in Asia, our findings suggest that the incidence and impact is similar to that noted in the West.
Among studies were molecular characterization of CDI was performed, the prevalence of hypervirulent ribotype 027 was only 0.3%. In comparison, this ribotype accounted for 21% of all C. difficile isolates[79] in the CDRN and 19% in the European EUCLID study.[76] While literature is not uniformly consistent on the impact of this strain, it has been associated with higher levels of toxin production and hypervirulence, [80, 81] leading to outbreaks initially in Canada and subsequently.[81] While the low prevalence among isolates in Asia is reassuring, the high rates of fluoroquinolone use in this population and the resistance of the ribotype 027 strain to this antibiotic class makes it essential to conduct regular surveillance for this strain.[13, 82]
There are several implications to our findings. Despite the recognition of CDI as an important HAI, there remains the perception of it being infrequent or inconsequential in Asia. In contrast to this, our results demonstrate both an incidence and mortality comparable to the west. Two narrative reviews, by Collins et al.[8] and Burke et al.[83] similarly emphasized the lack of awareness of CDI among physicians, that, along with our findings here, highlight the urgent need for education of healthcare professionals in Asia about its burden and impact. There is the need for appropriate infection control methods within hospitals including hand washing, contact isolation, minimization of unnecessary and over the counter dispensation of antibiotics, and development of antibiotic stewardship programs to reduce risk of CDI and prevent emergence of epidemic strains. The need for such measures attains additional urgency as several epidemiologic trends including aging of the population and growing burden of chronic disease favor escalation of CDI in Asia.
We readily acknowledge several limitations to evidence base contributing to our study. First, there was significant heterogeneity between the studies. However, a similar wide variation in incidence has also been observed across hospitals and between countries in the West. The heterogeneity was not completely explained by region, period of study, sample size, or testing strategy suggesting that either true variability in prevalence of CDI or the effect of other unmeasured factors. Second, nearly all the studies were conducted in a hospitalized setting and most did not differentiate community acquired from hospital acquired infection. As community acquired CDI may contribute to up to one-third of all CDI[84, 85], there is a need to systematically examine its occurrence globally. Only a few studies performed molecular characterization; there is the need for more robust data to accurately define the prevailing strains in Asia. Fourth, we observed evidence of publication bias and few studies reported on the impact of CDI on mortality or need for surgery. Finally, we searched the two most widely used medical literature databases—Embase and Pubmed—for relevant studies. However, we acknowledge that studies published solely in a regional language in Asia, particularly in smaller non-indexed journals, may not be comprehensively captured by these databases.
In conclusion, in this systematic review, we document that the burden of CDI in Asia is similar to that identified in North America and Europe. This highlights the need not only for further examination of the impact of C. difficile in this understudied geographic region but also the urgent need to educate providers about its consequence. There is also an important need for institution of appropriate measures to reduce the risk for development and transmission of this infection to reduce its adverse impact on patient outcomes.
Supporting information
S1 Table. Electronic search strategy for Pubmed.
https://doi.org/10.1371/journal.pone.0176797.s001
(DOC)
S2 Table. Meta-regression analysis to identify covariates influencing proportion of C. difficile positivity.
AAD—antibiotic associated diarrhea; EIA—Enzyme immuno assay; PCR—polymerase chain reaction.
https://doi.org/10.1371/journal.pone.0176797.s002
(DOC)
S3 Table. Quality of included studies using the Newcastle-Ottawa Quality Assessment Scale.
https://doi.org/10.1371/journal.pone.0176797.s003
(DOC)
S1 Checklist. PRISMA checklist for meta-analyses.
https://doi.org/10.1371/journal.pone.0176797.s004
(DOC)
S1 Dataset. Minimally identified dataset used for analysis.
https://doi.org/10.1371/journal.pone.0176797.s005
(XLS)
S1 Fig. Geographic distribution of proportion of tests positive for Clostridium difficile within Asia.
https://doi.org/10.1371/journal.pone.0176797.s006
(JPG)
S2 Fig. Secular trend in the proportion of stool tests that were positive for C. difficile.
https://doi.org/10.1371/journal.pone.0176797.s007
(JPG)
S3 Fig. Funnel plot for assessment of publication bias.
https://doi.org/10.1371/journal.pone.0176797.s008
(JPG)
Author Contributions
- Conceptualization: NZB SG SH AA.
- Data curation: NZB SG AA.
- Formal analysis: NZB AA.
- Supervision: AA.
- Writing – original draft: NZB AA.
- Writing – review & editing: SG SH AA.
References
- 1. George RH, Symonds JM, Dimock F, Brown JD, Arabi Y, Shinagawa N, et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J. 1978;1(6114):695. pmid:630301
- 2. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–34. pmid:25714160
- 3.
Barbut Fea. Clostridium difficile infection in Europe: a CDI Europe report 2013. http://www.multivu.com/assets/60637/documents/60637-CDI-HCP-Report-original.pdf.
- 4.
Agency) PHEfHP. Mandatory surveillance of Clostridium difficile. 2012. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1179746015058.
- 5. You E, Song H, Cho J, Lee J. Reduction in the incidence of hospital-acquired Clostridium difficile infection through infection control interventions other than the restriction of antimicrobial use. Int J Infect Dis. 2014;22:9–10. pmid:24583565
- 6. Marufu O, Desai N, Aldred D, Brown T, Eltringham I. Analysis of interventions to reduce the incidence of Clostridium difficile infection at a London teaching hospital trust, 2003–2011. J Hosp Infect. 2015;89(1):38–45. pmid:25480022
- 7. Mavros MN, Alexiou VG, Vardakas KZ, Tsokali K, Sardi TA, Falagas ME. Underestimation of Clostridium difficile infection among clinicians: an international survey. Eur J Clin Microbiol Infect Dis. 2012;31(9):2439–44. pmid:22450740
- 8. Collins DA, Hawkey PM, Riley TV. Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resist Infect Control. 2013;2(1):21. pmid:23816346
- 9. Hawkey PM, Marriott C, Liu WE, Jian ZJ, Gao Q, Ling TK, et al. Molecular epidemiology of Clostridium difficile infection in a major chinese hospital: an underrecognized problem in Asia? J Clin Microbiol. 2013;51(10):3308–13. pmid:23903542
- 10. Ziakas PD, Joyce N, Zacharioudakis IM, Zervou FN, Besdine RW, Mor V, et al. Prevalence and impact of Clostridium difficile infection in elderly residents of long-term care facilities, 2011: A nationwide study. Medicine (Baltimore). 2016;95(31):e4187.
- 11. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703. pmid:22047560
- 12. Bhatia R, Narain JP. The growing challenge of antimicrobial resistance in the South-East Asia Region—are we losing the battle? Indian J Med Res. 2010;132:482–6. pmid:21149995
- 13. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742–50. pmid:25022435
- 14. Kim J, Pai H, Seo MR, Kang JO. Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital. J Korean Med Sci. 2011;26(10):1258–64. pmid:22022175
- 15. Huang H, Wu S, Wang M, Zhang Y, Fang H, Palmgren AC, et al. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. Int J Antimicrob Agents. 2009;33(4):339–42. pmid:19097757
- 16. Hsu MS, Wang JT, Huang WK, Liu YC, Chang SC. Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan. J Microbiol Immunol Infect. 2006;39(3):242–8. pmid:16783456
- 17. Wongwanich S, Rugdeekha S, Pongpech P, Dhiraputra C. Detection of Clostridium difficile toxin A and B genes from stool samples of Thai diarrheal patients by polymerase chain reaction technique. J Med Assoc Thai. 2003;86(10):970–5. pmid:14650710
- 18. Tian TT, Zhao JH, Yang J, Qiang CX, Li ZR, Chen J, et al. Molecular Characterization of Clostridium difficile Isolates from Human Subjects and the Environment. PLoS One. 2016;11(3):e0151964. pmid:27011211
- 19. Lin HJ, Hung YP, Liu HC, Lee JC, Lee CI, Wu YH, et al. Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization. J Microbiol Immunol Infect. 2015;48(2):183–9. pmid:24064285
- 20. Warren CA, Labio E, Destura R, Sevilleja JE, Jamias JD, Daez ML. Clostridium difficile and Entamoeba histolytica infections in patients with colitis in the Philippines. Trans R Soc Trop Med Hyg. 2012;106(7):424–8. pmid:22657531
- 21. Mori N, Aoki Y. Clinical characteristics and risk factors for community-acquired Clostridium difficile infection: A retrospective, case-control study in a tertiary care hospital in Japan. J Infect Chemother. 2015;21(12):864–7. pmid:26482373
- 22. Li Y, Huang Y, Li Y, Nie Y. Clinical characteristics of Clostridium difficile-associated diarrhea among patients in a tertiary care center in China. Pak J Med Sci. 2016;32(3):736–41. pmid:27375724
- 23. Vaishnavi C, Singh M, Mahmood S, Kochhar R. Prevalence and molecular types of Clostridium difficile isolates from faecal specimens of patients in a tertiary care centre. J Med Microbiol. 2015;64(11):1297–304. pmid:26361995
- 24. Lee YC, Wang JT, Chen AC, Sheng WH, Chang SC, Chen YC. Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. J Microbiol Immunol Infect. 2012;45(4):287–95. pmid:22209696
- 25. Ingle M, Deshmukh A, Desai D, Abraham P, Joshi A, Rodrigues C, et al. Prevalence and clinical course of Clostridium difficile infection in a tertiary-care hospital: a retrospective analysis. Indian J Gastroenterol. 2011;30(2):89–93. pmid:21553102
- 26. Kim J, Kang JO, Kim H, Seo MR, Choi TY, Pai H, et al. Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea. Clin Microbiol Infect. 2013;19(6):521–7. pmid:22712697
- 27. Hsu LY, Tan TY, Koh TH, Kwa AL, Krishnan P, Tee NW, et al. Decline in Clostridium difficile-associated disease rates in Singapore public hospitals, 2006 to 2008. BMC Res Notes. 2011;4:77. pmid:21429188
- 28. Chung CH, Wu CJ, Lee HC, Yan JJ, Chang CM, Lee NY, et al. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis. J Microbiol Immunol Infect. 2010;43(2):119–25. pmid:20457428
- 29. Chaudhry R, Joshy L, Kumar L, Dhawan B. Changing pattern of Clostridium difficile associated diarrhoea in a tertiary care hospital: a 5 year retrospective study. Indian J Med Res. 2008;127(4):377–82. pmid:18577793
- 30. Alinejad F, Barati M, Satarzadeh Tabrisi M, Saberi M. Hospital acquired diarrhea in a burn center of Tehran. Iran J Microbiol. 2015;7(6):310–4. pmid:26885330
- 31. Chau ML, Hartantyo SH, Yap M, Kang JS, Aung KT, Gutierrez RA, et al. Diarrheagenic pathogens in adults attending a hospital in Singapore. BMC Infect Dis. 2016;16:32. pmid:26822615
- 32. Moukhaiber R, Araj GF, Kissoyan KA, Cheaito KA, Matar GM. Prevalence of Clostridium difficile toxinotypes in infected patients at a tertiary care center in Lebanon. J Infect Dev Ctries. 2015;9(7):732–5. pmid:26230123
- 33. Vaishnavi C, Singh M, Kapoor P, Kochhar R. Clinical and demographic profile of patients reporting for Clostridium difficile infection in a tertiary care hospital. Indian J Med Microbiol. 2015;33(2):326–7. pmid:25866002
- 34. Ji D, Huang IH, Lai CC, Wu FT, Jiang DD, Hsu BM, et al. Prevalence and characterization of enterotoxigenic Bacteroides fragilis and toxigenic Clostridium difficile in a Taipei emergency department. J Microbiol Immunol Infect. 2014.
- 35. Galaydick J, Xu Y, Sun L, Landon E, Weber SG, Sun D, et al. Seek and you shall find: prevalence of Clostridium difficile in Wuhan, China. Am J Infect Control. 2015;43(3):301–2. pmid:25557771
- 36. Wang X, Cai L, Yu R, Huang W, Zong Z. ICU-Onset Clostridium difficile infection in a university hospital in China: a prospective cohort study. PLoS One. 2014;9(11):e111735. pmid:25372033
- 37. Fang WJ, Jing DZ, Luo Y, Fu CY, Zhao P, Qian J, et al. Clostridium difficile carriage in hospitalized cancer patients: a prospective investigation in eastern China. BMC Infect Dis. 2014;14:523. pmid:25267108
- 38. Al-Thani AA, Hamdi WS, Al-Ansari NA, Doiphode SH, Wilson GJ. Polymerase chain reaction ribotyping of Clostridium difficile isolates in Qatar: a hospital-based study. BMC Infect Dis. 2014;14:502. pmid:25223337
- 39. Huang H, Wu S, Chen R, Xu S, Fang H, Weintraub A, et al. Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China. Anaerobe. 2014;30:65–9. pmid:25219941
- 40. Zhou FF, Wu S, Klena JD, Huang HH. Clinical characteristics of Clostridium difficile infection in hospitalized patients with antibiotic-associated diarrhea in a university hospital in China. Eur J Clin Microbiol Infect Dis. 2014;33(10):1773–9. pmid:24820293
- 41. Honda H, Yamazaki A, Sato Y, Dubberke ER. Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center. Anaerobe. 2014;25:5–10. pmid:24184291
- 42. Han XH, Du CX, Zhang CL, Zheng CL, Wang L, Li D, et al. Clostridium difficile infection in hospitalized cancer patients in Beijing, China is facilitated by receipt of cancer chemotherapy. Anaerobe. 2013;24:82–4. pmid:23770543
- 43. Hassan SA, Othman N, Idris FM, Abdul Rahman Z, Maning N, Abdul Rahman R, et al. Prevalence of Clostridium difficile toxin in diarhoeal stool samples of patients from a tertiary hospital in North Eastern Penisular Malaysia. Med J Malaysia. 2012;67(4):402–5. pmid:23082450
- 44. Hung YP, Tsai PJ, Hung KH, Liu HC, Lee CI, Lin HJ, et al. Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan. PLoS One. 2012;7(8):e42415. pmid:22876321
- 45. Jalali M, Khorvash F, Warriner K, Weese JS. Clostridium difficile infection in an Iranian hospital. BMC Res Notes. 2012;5:159. pmid:22436392
- 46. Vaishnavi C, Singh M. Preliminary investigation of environmental prevalence of Clostridium difficile affecting inpatients in a north Indian hospital. Indian J Med Microbiol. 2012;30(1):89–92. pmid:22361768
- 47. Nazemalhosseini-Mojarad E, Azimirad M, Razaghi M, Torabi P, Moosavi A, Alebouyeh M, et al. Frequency of Clostridium difficile among patients with gastrointestinal complaints. Gastroenterol Hepatol Bed Bench. 2011;4(4):210–3. pmid:24834184
- 48. Sadeghifard N, Salari MH, Ghassemi MR, Eshraghi S, Amin Harati F. The incidence of nosocomial toxigenic clostridium difficile associated diarrhea in Tehran tertiary medical centers. Acta Med Iran. 2010;48(5):320–5. pmid:21287466
- 49. Jamal W, Rotimi VO, Brazier J, Duerden BI. Analysis of prevalence, risk factors and molecular epidemiology of Clostridium difficile infection in Kuwait over a 3-year period. Anaerobe. 2010;16(6):560–5. pmid:20887795
- 50. Ergen EK, Akalin H, Yilmaz E, Sinirtas M, Alver O, Heper Y, et al. Nosocomial diarrhea and Clostridium Difficile associated diarrhea in a Turkish University Hospital. Med Mal Infect. 2009;39(6):382–7. pmid:19269761
- 51. Koh TH, Tan AL, Tan ML, Wang G, Song KP. Epidemiology of Clostridium difficile infection in a large teaching hospital in Singapore. Pathology. 2007;39(4):438–42. pmid:17676487
- 52. Kikkawa H, Hitomi S, Watanabe M. Prevalence of toxin A-nonproducing/toxin-B-producing Clostridium difficile in the Tsukuba-Tsuchiura district, Japan. J Infect Chemother. 2007;13(1):35–8. pmid:17334727
- 53. Cheng VC, Yam WC, Lam OT, Tsang JL, Tse EY, Siu GK, et al. Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong. Eur J Clin Microbiol Infect Dis. 2011;30(11):1371–81. pmid:21468685
- 54. Cheng VC, Yam WC, Chan JF, To KK, Ho PL, Yuen KY. Clostridium difficile ribotype 027 arrives in Hong Kong. Int J Antimicrob Agents. 2009;34(5):492–3. pmid:19464857
- 55. Lim PL, Barkham TM, Ling LM, Dimatatac F, Alfred T, Ang B. Increasing incidence of Clostridium difficile-associated disease, Singapore. Emerg Infect Dis. 2008;14(9):1487–9. pmid:18760029
- 56. Huang H, Wu S, Wang M, Zhang Y, Fang H, Palmgren AC, et al. Molecular and clinical characteristics of Clostridium difficile infection in a University Hospital in Shanghai, China. Clin Infect Dis. 2008;47(12):1606–8. pmid:19025371
- 57. Khan FY, Abu-Khattab M, Anand D, Baager K, Alaini A, Siddique MA, et al. Epidemiological features of Clostridium difficile infection among inpatients at Hamad General Hospital in the state of Qatar, 2006–2009. Travel Med Infect Dis. 2012;10(4):179–85. pmid:22800937
- 58. Choi HY, Park SY, Kim YA, Yoon TY, Choi JM, Choe BK, et al. The epidemiology and economic burden of Clostridium difficile infection in Korea. Biomed Res Int. 2015;2015:510386. pmid:25821807
- 59. Kim YS, Han DS, Kim YH, Kim WH, Kim JS, Kim HS, et al. Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. Epidemiol Infect. 2013;141(1):189–94. pmid:22717061
- 60. Lee YJ, Choi MG, Lim CH, Jung WR, Cho HS, Sung HY, et al. [Change of Clostridium difficile colitis during recent 10 years in Korea]. Korean J Gastroenterol. 2010;55(3):169–74. pmid:20357527
- 61. Lee JH, Lee SY, Kim YS, Park SW, Park SW, Jo SY, et al. [The incidence and clinical features of Clostridium difficile infection; single center study]. Korean J Gastroenterol. 2010;55(3):175–82. pmid:20357528
- 62. Thipmontree W, Kiratisin P, Manatsathit S, Thamlikitkul V. Epidemiology of suspected Clostridium difficile-associated hospital-acquired diarrhea in hospitalized patients at Siriraj Hospital. J Med Assoc Thai. 2011;94 Suppl 1:S207–16.
- 63. Thongkoom P, Kanchanahareutai S, Chantrakooptungkul S, Rahule S. Characteristics and Demographic Distributions of Toxigenic Clostridium difficile Strains in Rajavithi Hospital, 2009–2015. J Med Assoc Thai. 2016;99 Suppl 2:S195–200.
- 64. Kaneria MV, Paul S. Incidence of Clostridium difficile associated diarrhoea in a tertiary care hospital. J Assoc Physicians India. 2012;60:26–8.
- 65. Shehabi AA, Abu-Ragheb HA, Allaham NA. Prevalence of Clostridium difficile-associated diarrhoea among hospitalized Jordanian patients. East Mediterr Health J. 2001;7(4–5):750–5. pmid:15332775
- 66. Haider Naqvi SA, Chaudhry FF. Clostridium difficile postantibiotic diarrhoea diagnosis. J Coll Physicians Surg Pak. 2012;22(10):640–3. pmid:23058147
- 67. Shin BM, Kuak EY, Yoo HM, Kim EC, Lee K, Kang JO, et al. Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea: results of a retrospective study 2000–2005. J Med Microbiol. 2008;57(Pt 6):697–701. pmid:18480325
- 68. Ingle M, Deshmukh A, Desai D, Abraham P, Joshi A, Gupta T, et al. Clostridium difficile as a cause of acute diarrhea: a prospective study in a tertiary care center. Indian J Gastroenterol. 2013;32(3):179–83. pmid:23526401
- 69. Vishwanath S, Singhal A, D'Souza A, Mukhopadhyay C, Varma M, Bairy I. Clostridium difficile infection at a tertiary care hospital in south India. J Assoc Physicians India. 2013;61(11):804–6. pmid:24974492
- 70. Yang BK, Do BJ, Kim EJ, Lee JU, Kim MH, Kang JG, et al. The simple predictors of pseudomembranous colitis in patients with hospital-acquired diarrhea: a prospective observational study. Gut Liver. 2014;8(1):41–8. pmid:24516700
- 71. Zhu Y, Wang L, Feng S, Wang S, Zheng C, Wang J, et al. [Risk factors for Clostridium difficile-associated diarrhea among cancer patients]. Zhonghua Zhong Liu Za Zhi. 2014;36(10):773–7. pmid:25567310
- 72. Pittayanon R, Treeprasertsuk S, Phaosawasdi K, et al. The burden of Clostridium difficile infecion in Thais: nationwide survey. Asian Biomedicine. 2015;9(6):783–8.
- 73. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63–73. pmid:21084111
- 74. Cohen J, Limbago B, Dumyati G, Holzbauer S, Johnston H, Perlmutter R, et al. Impact of changes in Clostridium difficile testing practices on stool rejection policies and C. difficile positivity rates across multiple laboratories in the United States. J Clin Microbiol. 2014;52(2):632–4. pmid:24478500
- 75. Alcala L, Martin A, Marin M, Sanchez-Somolinos M, Catalan P, Pelaez T, et al. The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem? Clin Microbiol Infect. 2012;18(7):E204–13. pmid:22563775
- 76. Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis. 2014;14(12):1208–19. pmid:25455988
- 77. Centers for Disease C, Prevention. Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 2012;61(9):157–62. pmid:22398844
- 78. Lessa FC, Winston LG, McDonald LC, Emerging Infections Program CdST. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(24):2369–70. pmid:26061850
- 79. Wilcox MH, Shetty N, Fawley WN, Shemko M, Coen P, Birtles A, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis. 2012;55(8):1056–63. pmid:22784871
- 80. McDonald LC, Killgore GE, Thompson A, Owens RC Jr., Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433–41. pmid:16322603
- 81. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079–84. pmid:16182895
- 82. Kotwani A, Holloway K. Trends in antibiotic use among outpatients in New Delhi, India. BMC Infect Dis. 2011;11:99. pmid:21507212
- 83. Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6. pmid:24516694
- 84. Honda H, Dubberke ER. The changing epidemiology of Clostridium difficile infection. Curr Opin Gastroenterol. 2014;30(1):54–62. pmid:24285002
- 85. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008;62(2):388–96. pmid:18434341